Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo sinh học: " Improved gene delivery to human saphenous vein cells and tissue using a peptide-modified adenoviral vector Lorraine M Work1, Paul N Reynolds2 and Andrew H "

Tuyển tập các báo cáo nghiên cứu về sinh học được đăng trên tạp chí sinh học Journal of Biology đề tài: Improved gene delivery to human saphenous vein cells and tissue using a peptide-modified adenoviral vector Lorraine M Work1, Paul N Reynolds2 and Andrew H | Genetic Vaccines and Therapy BioMed Central Short paper Open Access Improved gene delivery to human saphenous vein cells and tissue using a peptide-modified adenoviral vector Lorraine M Work1 Paul N Reynolds2 and Andrew H Baker 1 Address 1BHF Glasgow Cardiovascular Research Centre Division of Cardiovascular Medical Sciences University of Glasgow 44 Church Street Glasgow G11 6NT UK and 2Royal Adelaide Hospital Chest Clinic and Department of Medicine University of Adelaide Adelaide South Australia Australia Email Lorraine M Work - lmw3u@clinmed.gla.ac.uk Paul N Reynolds - paul.reynolds@adelaide.edu.au Andrew H Baker - ab11f@clinmed.gla.ac.uk Corresponding author Published 08 October 2004 Received 10 September 2004 Accepted 08 October 2004 Genetic Vaccines and Therapy 2004 2 14 doi 10.1186 1479-0556-2-14 H This article is available from http www.gvt-journal.com content 2 l l4 2004 Work et al licensee BioMed Central Ltd. This is an open-access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract The establishment of efficient gene delivery to target human tissue is a major obstacle for transition of gene therapy from the pre-clinical phases to the clinic. The poor long-term patency rates for coronary artery bypass grafting CABG is a major clinical problem that lacks an effective and proven pharmacological intervention. Late vein graft failure occurs due to neointima formation and accelerated atherosclerosis. Since CABG allows a clinical window of opportunity to genetically modify vein ex vivo prior to grafting it represents an ideal opportunity to develop gene-based therapies. Adenoviral vectors have been frequently used for gene delivery to vein ex vivo and pre-clinical studies have shown effective blockade in neointima development by overexpression of candidate therapeutic